ArticlePharmacotherapy2022
Comparison of Bayesian-derived and first-order analytic equations for calculation of vancomycin area under the curve.
Article in Pharmacotherapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.
- Vancomycin area under the curve versus trough only guided dosing and the risk of acute kidney injury: Systematic review and meta-analysis.Pharmacotherapy · 2022Pooled it
- Observed Trough-Based Vancomycin Dosing Decisions Versus Model-Predicted Bayesian AUC-Guided Recommendations.Healthcare (Basel, Switzerland) · 2026Article
- Comparison of Bayesian and First-Order Estimations of Vancomycin Area Under the Curve in Pediatrics Using One- and Two-Concentration Methods.Pharmacotherapy · 2026Article
- Real-World Comparison of Trough- and Online-Bayesian-Calculator-Derived AUCPharmaceuticals (Basel, Switzerland) · 2026Article
- Evaluation of Vancomycin Therapeutic Drug Monitoring Strategies: Pharmacokinetic, Pharmacogenetic, and Clinical Perspectives in a Prospective, Real-World Cohort Study.European journal of clinical pharmacology · 2026Article
- Bayesian Estimation of Vancomycin Exposure and Population Pharmacokinetics in Obese Patients.Antibiotics (Basel, Switzerland) · 2026Article
- Pharmacokinetics and Customized Dosing of Vancomycin in Adult Patients With Hematological Malignancies: Status, Challenges, and Opportunities.Pharmacology research & perspectives · 2026Review
- Adverse events leading to discontinuation of daptomycin versus vancomycin in outpatient parenteral antimicrobial therapy: a retrospective cohort study.JAC-antimicrobial resistance · 2025Article
- Use of nomograms based on the one-compartment model in the estimation of area under the blood concentration-time curve of vancomycin: a retrospective cohort study.European journal of clinical pharmacology · 2025Article
- Impact of Sampling Strategy and Population Model on Bayesian Estimates of Vancomycin AUC in Patients with BMI > 40 kg/mMedicines (Basel, Switzerland) · 2025Article
- Retrospective Bayesian Reanalysis of Single Gentamicin Concentrations: A Neonatal Case Series.Medicines (Basel, Switzerland) · 2025Article
- Are All Pharmacokinetic Equations Created Equal? A Comparative Analysis of Trapezoidal and Non-Trapezoidal Methods for Estimating Day 1 Area Under the Curve in Adult Hospitalized Patients with Staphylococcus aureus Bacteremia.Infectious diseases and therapy · 2025Article
- Vancomycin levels for Bayesian dose-optimization in critical care: a prospective cohort study.Frontiers in medicine · 2025Article
- Automated calculation and reporting of vancomycin area under the concentration-time curve: a simplified single-trough concentration-based equation approach.Antimicrobial agents and chemotherapy · 2024Article
- Characterizing Day 1 Area Under the Curve Following Vancomycin Loading Dose Administration in Adult Hospitalized Patients Using Non-Trapezoidal Linear Pharmacokinetic Equations: A Retrospective Observational Study.Infectious diseases and therapy · 2024Article
- Evaluation of Vancomycin Area Under the Concentration-Time Curve Predictive Performance Using Bayesian Modeling Software With and Without Peak Concentration: An Academic Hospital Experience for Adult Patients Without Renal Impairment.Annals of laboratory medicine · 2023Article
- Acute Kidney Injury Incidence With Bayesian Dosing Software Versus 2-Level First-Order Area Under the Curve-Based Dosing of Vancomycin With Piperacillin-Tazobactam.The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians · 2023Article
- Altered Pharmacokinetics Parameters of Vancomycin in Patients with Hematological Malignancy with Febrile Neutropenia, a Bayesian Software Estimation.Antibiotics (Basel, Switzerland) · 2023Article
- Implementing Vancomycin Population Pharmacokinetic Models: An App for Individualized Antibiotic Therapy in Critically Ill Patients.Antibiotics (Basel, Switzerland) · 2023Article
- The Bayesian-Based Area under the Curve of Vancomycin by Using a Single Trough Level: An Evaluation of Accuracy and Discordance at Tertiary Care Hospital in KSA.Healthcare (Basel, Switzerland) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
introductionConsensus guidelines recommend targeting a vancomycin area under the curve to minimum inhibitory concentration (AUC
objectiveTo compare calculated vancomycin AUC
methodsThis was a single-center, retrospective cohort study of 978 adult hospitalized patients receiving intravenous vancomycin between 2017 and 2019. Patients were included if they received at least 72 h of vancomycin and had two-serum drug concentrations obtained. AUC
resultsExcellent agreement was observed between linear and Bayesian two-concentration methods (r = 0.963, clinical agreement = 87.4%) and Bayesian two-concentration and one-concentration methods (r = 0.931, clinical agreement = 88.5%); however, a degree of variability was noted with 95% LOA -99 to 76 (MD = -11.5 mg*h/L) and -92 to 113 (MD = -10.4 mg*h/L), for the respective comparisons. The agreement between linear and Bayesian one-concentration approaches was less than prior comparisons (r = 0.823, clinical agreement = 76.8%) and demonstrated the greatest amount of variability with 95% LOA -197 to 153 (MD = -21.9 mg*h/L).
conclusionsLinear and Bayesian two-concentration methods demonstrated high-level agreement with acceptable variability and may be considered comparable to estimate vancomycin AUC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.